Dr. Philip McMillan,  John McMillan

Eight fifty-one in the morning, May 27, 2021. Janet Woodcock, one of the most senior officials at the Food and Drug Administration, sent an email to Francis Collins at the NIH and Anthony Fauci at NIAID. The subject was not supply, and it was not boosters. She was writing about ordinary people who were getting sick after vaccination, and about the awkward fact that nobody could work out what was wrong with them.

That email surfaced this month, five years later, released by Senators Ron Johnson and Rand Paul from a document trove running past a thousand pages. Anyone searching their local news for it will turn up plenty about the Senate hearings, about contempt proceedings, about who is defending Fauci and who is calling for his head. The email itself is considerably harder to find.

The distance between what regulators were saying to each other in private and what the public has been told since is the actual story here, and it deserves a careful reading rather than being shouted out.

The Patients Nobody Could Categorise

Woodcock’s message was short and, for a senior regulator, remarkably plain. She had been contacted by a number of people who had experienced adverse events after COVID vaccination. Not from one product: from all three then available in the United States. Many of those reaching out were health care professionals. Some she knew personally. Then came the line that explains much of the silence that followed: “The symptoms do not fit together into a distinctive syndrome and most are not easily quantifiable or evaluated with standard laboratory testing.”

That sentence describes a particular kind of medical orphan. American vaccine safety monitoring is built to catch things that announce themselves: a fever inside 48 hours, anaphylaxis on the clinic floor, a clot that lights up on a scan. VAERS, the Vaccine Adverse Event Reporting System, handles that sort of signal reasonably well. What it cannot handle is a patient who is simply, stubbornly unwell, exhausted and foggy and aching, sleeping badly, unable to name the thing that is wrong. Such a patient is rarely admitted, rarely given a diagnostic code, and almost never becomes a row in anybody’s database. Woodcock said as much herself, noting that this pattern would slip past VAERS, past the CDC’s active follow-up, past medical record surveillance altogether. A blind spot she could see perfectly clearly, and flagged, in writing, to the two men best placed to close it.

Why the Study Was Never Going to Happen

So what happens to a signal the instruments cannot pick up? Someone has to go and look directly, gathering the patients, examining them, characterizing the pattern, publishing whatever emerges. Woodcock proposed exactly that. Money would be needed, she wrote, along with an investigator who had an appetite for a medical mystery. Then, in the same breath, she explained why it probably would not happen: “I doubt the industry would support [it] for obvious reasons.”

She was not being coy. Manufacturers had already delivered the trials that public health agencies cared about, the ones showing reduced severe disease. Government handled the marketing free of charge. Liability had been lifted off the balance sheet. From a purely commercial standpoint the arrangement was close to perfect, and no company goes hunting for its own product’s rare failure mode when the alternative is to say nothing and keep shipping. Conspiracy is the wrong word for it. The incentives pointed one way, and Woodcock understood them well enough to put the problem in writing to her colleagues.

What the Illness Might Actually Be

Five years on, the group she described still has no agreed name in the medical literature, no diagnostic criteria, no treatment protocol. What it has is a hypothesis, worth taking seriously precisely because it can be tested and thrown out if wrong. Suspicion falls on the spike protein itself rather than on any one vaccine platform, which is what Woodcock’s all-three-vaccines detail quietly points toward. Met through infection or through vaccination, the protein may in some people fail to clear completely. In those already carrying low-grade inflammation, embers rather than open fire, the leftover fragments appear to keep the immune system agitated indefinitely.

One clue supports this more than any other, and it was brushed aside when it first appeared. A number of long COVID patients reported that their symptoms improved briefly after vaccination, then returned. That pattern fits an immune system producing IgG4 antibodies, a class associated with tolerance rather than attack. The response quiets down, the patient feels better for a while, and nothing underneath has actually been cleared. It is an elegant explanation, still unproven, and still waiting on the exact study Woodcock said nobody would pay for.

Precision matters here, and it cuts against comfortable stories on every side. Long COVID existed before any vaccine did. People infected in March 2020, never vaccinated, remain unwell today. Research showing that vaccination lowers long COVID risk is probably right as far as it goes, largely because vaccinated people avoid the severe lung, heart and kidney damage that gets filed under the same heading. Complications of severe COVID-19 are not the same thing as a diffuse post-vaccination illness, even when a spreadsheet treats them identically. Blurring the two makes the data look tidier than reality, and tidy data is precisely how an internal FDA warning goes untouched for five years.

Four Months to the Mandates

The timeline is the part that stings. Woodcock wrote in May 2021. The mandates arrived that September. Four months, with no public record of anyone investigating the pattern she had flagged in between. That leaves a particular group of people carrying the cost. The nurse who did not want it and took it anyway, because the alternative was surrendering her registration. The teacher. The pilot. The care worker on a zero-hours contract. People who complied under pressure, got sick afterward, and have spent five years being told it is stress, or anxiety, or long COVID from an infection they cannot remember catching. Many of them will not entertain the possibility that the vaccine played any part, which is its own quiet tragedy, and which happens to suit everybody else beautifully.

None of this argues for abandoning vaccination, and it should not be read that way. It argues for something far smaller and completely achievable: funding the study Woodcock asked for in 2021, characterizing the syndrome properly, and giving these patients a name for what they have along with a clinician who believes them. Post-pandemic inflammatory disease numbers are climbing, and sooner or later a great many people are going to connect their own decline to a decision they were pushed into making. Woodcock saw the shape of it coming. Let a problem fester, she warned her colleagues, and it will come back to bite you later, when you are not prepared. Five years on, in a Senate hearing room, it has started biting.